To see the other types of publications on this topic, follow the link: Nihon Seikō.

Journal articles on the topic 'Nihon Seikō'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 21 journal articles for your research on the topic 'Nihon Seikō.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

OOKAWA, Shigeru, and Satoshi KITAZONO. "Production of Antimony Compounds at Nakase Refinery, Nihon Seiko Co., Ltd." Journal of MMIJ 123, no. 12 (2007): 715–18. http://dx.doi.org/10.2473/journalofmmij.123.715.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

MIYAKE, A. "Shir zu sengo Nihon shakai no rekishi, 1. Kawaru shakai, kawaru hitobito: 20-seiki no naka no sengo Nihon (The Social History of Postwar Japan, Vol. 1. Changing Society, Changing Individuals: Japan's Postwar 20th Century)." Social Science Japan Journal 18, no. 1 (2014): 109–12. http://dx.doi.org/10.1093/ssjj/jyu028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Grachyov, Maxim. "Ideas About Natural Disasters as the “Natural Course of Things” and “Sango Years” in Ancient and Early Medieval Japan." ISTORIYA 13, no. 12-1 (122) (2022): 0. http://dx.doi.org/10.18254/s207987840023889-6.

Full text
Abstract:
The perception of natural disasters as a manifestation of work of supernatural forces was spread around the world during those periods of history when scientific knowledge was not developed enough to explain the mechanisms of natural phenomena. Japan, due to its geographical features, was regularly prone to all kinds of destructive natural forces, so it was it was touched by these ideas as well. The view on natural disasters as a form of divine retribution from Heaven for “immoral” ruling has been known in Japan since the establishment of the “state based on laws” (ritsuryo kokka), and often a
APA, Harvard, Vancouver, ISO, and other styles
4

KONDO, Ayako. "Seiki no Sekai • Hiseiki no sekai: Gendai nihon rōdō keizaigaku no kihon mondai (The World of Regular Employees The World of Non-regular Employees: Fundamental Issues in Labor Economics in Japan Today)." Social Science Japan Journal 22, no. 1 (2019): 172–76. http://dx.doi.org/10.1093/ssjj/jyy055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nagane, Motoo, Yoshitaka Narita, Kazuhiko Mishima, et al. "Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)." Blood 134, Supplement_1 (2019): 1586. http://dx.doi.org/10.1182/blood-2019-123362.

Full text
Abstract:
BACKGROUND The first-generation Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL). Tirabrutinib is a second-generation oral BTK inhibitor with greater selectivity than ibrutinib. We evaluated the safety, tolerability, efficacy, and pharmacokinetics (PK) of tirabrutinib once daily (QD) as monotherapy in patients with PCNSL to investigate BTK targeting as a novel therapeutic strategy. This multicenter clinical trial was sponsored by Ono Pharmaceutical Co., Ltd. and was conducted in Japan. MET
APA, Harvard, Vancouver, ISO, and other styles
6

Boot, W. J. "Nihon seiji shisōshi: 17–19 seiki 日本政治思想史――十七〜十九世紀. By Watanabe Hiroshi 渡辺 浩. Tokyo: Tōkyō Daigaku Shuppankai, 2010. Pp. 484. ISBN 10: 4130331000; 13: 9784130331005." International Journal of Asian Studies 10, № 1 (2013): 106–8. http://dx.doi.org/10.1017/s1479591412000332.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Terui, Yasuhito, Yoshitaka Narita, Motoo Nagane, et al. "Quality of Life and Karnofsky Performance Status in Patients with Relapse or Refractory Primary Central Nervous System Lymphoma during Phase I/II Study of Tirabrutinib." Blood 138, Supplement 1 (2021): 4561. http://dx.doi.org/10.1182/blood-2021-146439.

Full text
Abstract:
Abstract Background: Based on the results of a phase I/II study in Japan (Trial registration: JapicCTI-173646), tirabrutinib (TIR), a second-generation inhibitor of Bruton's tyrosine kinase, was approved in March 2020 for the treatment of relapsed or refractory primary central nervous system lymphoma (r/r PCNSL). We have previously reported overall response rate of 63.6% and manageable safety profile results of this study (Narita et al. Neuro Oncol. 2021;23(1):122-133). Further, one-year follow-up data after the last patient had enrolled showed that the effects of TIR persisted in r/r PCNSL pa
APA, Harvard, Vancouver, ISO, and other styles
8

Yamauchi, Nobuhiko, Dai Maruyama, Ilseung Choi, et al. "Impact of Prophylactic Antiviral Therapy on Clinical Outcomes of Hepatitis B Virus Surface Antigen Positive Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy." Blood 132, Supplement 1 (2018): 4209. http://dx.doi.org/10.1182/blood-2018-99-114850.

Full text
Abstract:
Abstract <Introduction> Hepatitis B virus (HBV) surface antigen (HBsAg)-positive patients treated with anti-B-cell lymphoma therapy are at high risk of HBV reactivation; indeed, the incidence is as high as 60-80% without antiviral prophylaxis. Hepatitis caused by HBV reactivation usually leads to discontinuation of chemotherapy, which in itself may be fatal. Therefore, several guidelines recommend antiviral prophylaxis for HBsAg-positive patients treated with chemotherapy. However, there is limited evidence regarding the clinical impact of antiviral prophylaxis on HBV reactivation and su
APA, Harvard, Vancouver, ISO, and other styles
9

Ohmachi, Ken, Tomohiro Kinoshita, Kensei Tobinai, et al. "Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601." Blood 132, Supplement 1 (2018): 4194. http://dx.doi.org/10.1182/blood-2018-99-110201.

Full text
Abstract:
Abstract Background: CHOP plus rituximab (R-CHOP) is the standard of care for previously untreated DLBCL. R-CHOP comprises CHOP and one-dose rituximab in each 21-day cycle; however, the schedule of rituximab administration has not been fully optimized. Dose-dense rituximab was expected to increase its peak concentration to enhance the synergistic effect with chemotherapy at early phase of treatment. To compare weekly administration of rituximab combined with CHOP (RW-CHOP) with standard R-CHOP in patients with previously untreated DLBCL, we conducted a multicenter, randomized phase II/III stud
APA, Harvard, Vancouver, ISO, and other styles
10

Fujimoto, Ayumi, Fumihiro Ishida, Koji Izutsu, et al. "Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Aggressive Natural Killer Cell Leukemia: An Advantage of Cord Blood Transplantation." Blood 134, Supplement_1 (2019): 2032. http://dx.doi.org/10.1182/blood-2019-122049.

Full text
Abstract:
Introduction Aggressive natural killer cell leukemia (ANKL) is a rare leukemic form of mature natural killer cell neoplasms that is closely associated with Epstein-Barr virus. ANKL presents a fulminant clinical course, resulting in a poor prognosis with a median overall survival of approximately 2 months. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment, but the long-term outcomes after allo-HSCT remain unclear. Methods Using the national Japanese transplant registry database, the outcomes of 59 ANKL patients who underwent first allo-HSCT
APA, Harvard, Vancouver, ISO, and other styles
11

Fujioka, Yuki, Naoto Takahashi, Shigeki Ohtake, et al. "Nilotinib and Dasatinib Evoked Distinct Immune Effects during Tfr Phase of Each Discontinuation Trial." Blood 138, Supplement 1 (2021): 3580. http://dx.doi.org/10.1182/blood-2021-147312.

Full text
Abstract:
Abstract Introduction: Tyrosine kinase inhibitor (TKI) has dramatically improved the prognosis of chronic myeloid leukemia (CML) patients. Recently, many trials of TKI discontinuation revealed that approximately 40% to 60% of CML patients who received long time TKI therapy reached the treatment-free remission (TFR), thus now TFR is proposed as one of the goals in CML treatment. Achieving deep molecular response (DMR) by TKI therapy is a minimum requirement of a challenge to TKI discontinuation in CML patient, actually CML patients with molecular residual disease (MRD) showed worse consequence
APA, Harvard, Vancouver, ISO, and other styles
12

Harada, Naonori, Hiroshi Okamura, Hideo Koh, et al. "A Prospective Comparison Analysis of Blood Biomarkers for the Diagnosis and Prediction of Sinusoidal Obstruction Syndrome." Blood 138, Supplement 1 (2021): 2865. http://dx.doi.org/10.1182/blood-2021-146497.

Full text
Abstract:
Abstract Background: Sinusoidal obstruction syndrome (SOS) remains a significant, potentially lethal complication after allogeneic hematopoietic cell transplantation (allo-HCT). Although a liver biopsy is required to diagnose SOS accurately, it is not considered a mandatory evaluation due to its invasiveness. Therefore, the Seattle and Baltimore criteria with minor revisions have been widely used. However, the diagnostic accuracy of those criteria is insufficient. A noninvasive and more accurate diagnostic strategy is necessary. A number of studies have reported several candidate blood biomark
APA, Harvard, Vancouver, ISO, and other styles
13

Suzuki, Tomotaka, Suguru Fukuhara, Junko Nomoto, et al. "Genomics of Limited-Stage Diffuse Large B-Cell Lymphoma Developing Late Relapse: Analysis of Gene Alterations in Paired Primary and Late Relapsed Tumors By Target Sequencing." Blood 132, Supplement 1 (2018): 1571. http://dx.doi.org/10.1182/blood-2018-99-111262.

Full text
Abstract:
Abstract Introduction: In limited-stage diffuse large B-cell lymphoma (DLBCL), a continued risk of relapse has been reported (Stephens et al. J Clin Oncol 2016). Another report highlighted that initial limited-stage DLBCL, a favorable International Prognostic Index and extranodal involvement seemed to be risk factors for late relapse (LR; Larouche et al. J Clin Oncol 2010). However, even if a subgroup of patients (pts) with LR shows distinct clinical characteristics, the underlying biology is largely unknown. Methods: Nineteen consecutive pts who developed LR were identified among 337 pts with
APA, Harvard, Vancouver, ISO, and other styles
14

Morishima, Satoko, Kenji Ishitsuka, Koji Izutsu, et al. "First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)." Blood 134, Supplement_1 (2019): 4025. http://dx.doi.org/10.1182/blood-2019-125507.

Full text
Abstract:
Introduction: Enhancer of zeste homolog 2 (EZH2) and EZH1 are alternative subunits of polycomb repressive complex 2 that catalyze the tri-methylation of lysine 27 residue of histone H3. This histone modification epigenetically regulates gene expression and may play an important role in tumor progression. Valemetostat (DS-3201) is a potent and highly specific orally bioavailable dual inhibitor of EZH2 and EZH1 demonstrating anti-tumor activity against various hematological malignancies in preclinical studies (Honma D, et al. Cancer Sci 2017; Fujita S, et al. Leukemia 2018). Valemetostat demonst
APA, Harvard, Vancouver, ISO, and other styles
15

Ono, Takaaki, Masayuki Hino, Itaru Matsumura, et al. "Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study." Blood 138, Supplement 1 (2021): 2557. http://dx.doi.org/10.1182/blood-2021-145164.

Full text
Abstract:
Abstract Introduction : Bosutinib is approved in Japan for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and Ph+ CML resistant/intolerant to prior therapy. In the primary report of a phase 2 study of first-line bosutinib in Japanese patients with CP CML (NCT03128411), the major molecular response (MMR) rate at 12 months was 55.0% and adverse events (AEs) were manageable and consistent with the known safety profile of bosutinib. Here we report the final 3-year efficacy and safety results of this phase 2 study. Methods : Ja
APA, Harvard, Vancouver, ISO, and other styles
16

Leonard, John P., Marek Trněný, Koji Izutsu, et al. "AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma." Blood 132, Supplement 1 (2018): 445. http://dx.doi.org/10.1182/blood-2018-99-110861.

Full text
Abstract:
Abstract Background: Indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma (FL) and marginal zone lymphoma (MZL), is typically responsive to initial chemoimmunotherapy, but relapse is expected. Single-agent rituximab is FDA approved and frequently administered for patients with relapsed/refractory (R/R) low-grade or follicular CD20-positive B-cell NHL. Lenalidomide is an immunomodulatory agent with preclinical and clinical antilymphoma activity alone and in combination with rituximab. We compared the efficacy and safety of lenalidomide plus rituximab (R2) to rituximab (plus place
APA, Harvard, Vancouver, ISO, and other styles
17

"Nihon Seiko acquires Nippon Atomized Metal Powders." Metal Powder Report 55, no. 10 (2000): 10. http://dx.doi.org/10.1016/s0026-0657(00)93162-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

"Nihon Seiko to market two new antimony compounds." Focus on Powder Coatings 2012, no. 4 (2012): 5. http://dx.doi.org/10.1016/s1364-5439(12)70088-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Farkas, Mária Ildikó. "Civilizáció, modernizáció: Japán a 19. században." Távol-keleti Tanulmányok 11, no. 2019/1 (2020). http://dx.doi.org/10.38144/tkt.2019.1.8.

Full text
Abstract:
Karube Tadashi: Toward the Meiji revolution. The Search for „Civilization” in Nineteenth-Century Japan. JPIC Tokyo, 2019. Japan Publishing Industry Foundation for Culture. transl. by David Noble, from „Ishin kakumei” e no michi: „Bunmei” o motomeru jūkyū seiki Nihon Shinchosha Publishing Co., Ltd. 2017
APA, Harvard, Vancouver, ISO, and other styles
20

"Development of auto-deposition painting Toshiya Kojima, Hideo Yano (Aisin Seiki Co., Ltd.), Motoo Nakano, Hitoshi Ishii (Nihon Parkerizing Co., Ltd.)." JSAE Review 17, no. 4 (1996): 442. http://dx.doi.org/10.1016/s0389-4304(96)80558-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

"9731451 Development of a system to construct 3D models from 2D drawings Hiroshi Sakai, Shuzaburo Fujii (Aisin Seiki Co., Ltd.), Ryo Haruta (Nihon Unisys, Ltd.)." JSAE Review 19, no. 1 (1998): 91. http://dx.doi.org/10.1016/s0389-4304(98)90233-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!